BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38836687)

  • 1. Decoding LY6G6D in colorectal cancer: Unraveling biomarker potential and therapeutic insights.
    Naqvi M; Abbasi WA; Samma MK; Gabol AA; Innocent C; Iqbal S; Fatima S; Ali K
    Cell Mol Biol (Noisy-le-grand); 2024 Jun; 70(6):14-20. PubMed ID: 38836687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D.
    Sanvicente García A; Pedregal M; Paniagua-Herranz L; Díaz-Tejeiro C; Nieto-Jiménez C; Pérez Segura P; Munkácsy G; Győrffy B; Calvo E; Moreno V; Ocaña A
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
    Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
    J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.
    Corrales L; Hipp S; Martin K; Sabarth N; Tirapu I; Fuchs K; Thaler B; Walterskirchen C; Bauer K; Fabits M; Bergmann M; Binder C; Chetta PM; Vogt AB; Adam PJ
    Front Immunol; 2022; 13():1008764. PubMed ID: 36159851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-surface markers for colon adenoma and adenocarcinoma.
    Sewda K; Coppola D; Enkemann S; Yue B; Kim J; Lopez AS; Wojtkowiak JW; Stark VE; Morse B; Shibata D; Vignesh S; Morse DL
    Oncotarget; 2016 Apr; 7(14):17773-89. PubMed ID: 26894861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
    Wang P; Sun LL; Clark R; Hristopoulos M; Chiu CPC; Dillon M; Lin W; Lo AA; Chalsani S; Das Thakur M; Zimmerman Savill KM; Rougé L; Lupardus P; Piskol R; Husain B; Ellerman D; Shivva V; Leong SR; Ovacik M; Totpal K; Wu Y; Spiess C; Lee G; Leipold DD; Polson AG
    Mol Cancer Ther; 2022 Jun; 21(6):974-985. PubMed ID: 35364611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer.
    Susmi TF; Rahman A; Khan MMR; Yasmin F; Islam MS; Nasif O; Alharbi SA; Batiha GE; Hossain MU
    BMC Cancer; 2021 May; 21(1):577. PubMed ID: 34016083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study.
    Chiang SF; Kan CY; Hsiao YC; Tang R; Hsieh LL; Chiang JM; Tsai WS; Yeh CY; Hsieh PS; Liang Y; Chen JS; Yu JS
    Dis Markers; 2015; 2015():874054. PubMed ID: 26494939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis.
    Xu H; Liu Y; Cheng P; Wang C; Liu Y; Zhou W; Xu Y; Ji G
    J Exp Clin Cancer Res; 2020 Dec; 39(1):283. PubMed ID: 33317596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of epigenetic silencing of the SFRP2 gene in colorectal cancer as a clinical biomarker and molecular significance.
    Boughanem H; Pilo J; García-Flores LA; Arranz I; Ramos-Fernandez M; Ortega-Castan M; Crujeiras AB; Sandoval J; Macias-Gonzalez M
    J Transl Med; 2024 May; 22(1):509. PubMed ID: 38802858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of long non-coding RNA RP11-708H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway.
    Sun L; Jiang C; Xu C; Xue H; Zhou H; Gu L; Liu Y; Xu Q
    Oncotarget; 2017 Apr; 8(17):27929-27942. PubMed ID: 28427191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer.
    Wang D; Liufu J; Yang Q; Dai S; Wang J; Xie B
    Biol Direct; 2022 Nov; 17(1):29. PubMed ID: 36319976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer.
    Zhao C; Chen J; Liu Y; Ju S; Wang G; Wang X
    Bioengineered; 2021 Dec; 12(2):11648-11661. PubMed ID: 34699318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer.
    Han CL; Chen JS; Chan EC; Wu CP; Yu KH; Chen KT; Tsou CC; Tsai CF; Chien CW; Kuo YB; Lin PY; Yu JS; Hsueh C; Chen MC; Chan CC; Chang YS; Chen YJ
    Mol Cell Proteomics; 2011 Apr; 10(4):M110.003087. PubMed ID: 21209152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma.
    Kim HS; Yoon G; Do SI; Kim SJ; Kim YW
    Oncotarget; 2016 Mar; 7(12):15187-99. PubMed ID: 26942563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-146a promote cell migration and invasion in human colorectal cancer via carboxypeptidase M/src-FAK pathway.
    Lu D; Yao Q; Zhan C; Le-Meng Z; Liu H; Cai Y; Tu C; Li X; Zou Y; Zhang S
    Oncotarget; 2017 Apr; 8(14):22674-22684. PubMed ID: 28186967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and diagnostic potential of hsa_circ_101303 in colorectal cancer: unraveling a regulatory network.
    Li KZ; Liao XM; Li SQ; Wei HT; Liang ZJ; Ge LX; Zhou SF; Hu BL
    BMC Cancer; 2024 Jun; 24(1):671. PubMed ID: 38824581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin expression and its prognostic role according to microsatellite instability status in colorectal adenocarcinoma.
    Kim H; Chung Y; Paik SS; Jang K; Shin SJ
    Medicine (Baltimore); 2019 Jun; 98(26):e16207. PubMed ID: 31261569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased Expression of MIR-134 and its Clinical Significance in Human Colorectal Cancer.
    Xie Y; Song J; Zong Q; Wang A; Yang Y; Liu F; Meng X
    Hepatogastroenterology; 2015 May; 62(139):615-9. PubMed ID: 26897940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAMTSL2 is a potential prognostic biomarker and immunotherapeutic target for colorectal cancer: Bioinformatic analysis and experimental verification.
    Huang Z; Hu X; Wei Y; Lai Y; Qi J; Pang J; Huang K; Li H; Cai P
    PLoS One; 2024; 19(5):e0303909. PubMed ID: 38814950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.